

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934  
(Amendment No. \_\_\_\_1\_\_\_\_)\*

Cytoclonal Pharmaceuticals Inc.

-----  
(Name of Issuer)

Common Stock, \$.01 par value

-----  
(Title of Class of Securities)

23282G105

-----  
(CUSIP Number)

Check the following box if a fee is being paid with this statement ☐.

(A fee is not required only if the filing person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 7 pages

CUSIP No. 23282G105

13G

Page 2 of 7 Pages

-----  
1 NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Kinder Investments, L.P.

-----  
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*  
(a) ☐  
(b) ☐

-----  
3 SEC USE ONLY

-----  
4 CITIZENSHIP OR PLACE OF ORGANIZATION

New York

-----  
NUMBER OF 5 SOLE VOTING POWER  
SHARES 0

BENEFICIALLY -----

OWNED BY 6 SHARED VOTING POWER  
EACH 708,000

REPORTING -----

PERSON 7 SOLE DISPOSITIVE POWER  
WITH 0

-----  
8 SHARED DISPOSITIVE POWER  
708,000

-----  
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

708,000

-----  
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\*

-----  
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

8.1%

-----  
12 TYPE OF REPORTING PERSON\*

PN

-----  
\*SEE INSTRUCTIONS BEFORE FILLING OUT

CUSIP No. 23282G105

13G

Page 3 of 7 Pages

-----  
1 NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Peyser Associates, LLC

-----  
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a) [ ]

(b) [ ]

-----  
3 SEC USE ONLY  
-----

4 CITIZENSHIP OR PLACE OF ORGANIZATION

New York

NUMBER OF 5 SOLE VOTING POWER  
SHARES 0

BENEFICIALLY

OWNED BY 6 SHARED VOTING POWER  
EACH 708,000

REPORTING

PERSON 7 SOLE DISPOSITIVE POWER  
WITH 0

8 SHARED DISPOSITIVE POWER

708,000

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

708,000

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\*

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

8.1%

12 TYPE OF REPORTING PERSON\*

CO.

\*SEE INSTRUCTIONS BEFORE FILLING OUT

CUSIP No. 23282G105

13G

Page 4 of 7 Pages

1 NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Brian A. Wasserman

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a) ☐

(b) ☐

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF 5 SOLE VOTING POWER  
SHARES 708,000

BENEFICIALLY -----  
OWNED BY 6 SHARED VOTING POWER  
EACH 0  
REPORTING -----  
PERSON 7 SOLE DISPOSITIVE POWER  
WITH 708,000  
-----  
8 SHARED DISPOSITIVE POWER  
  
0

-----  
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

708,000

-----  
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES\*

-----  
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

8.1%

-----  
12 TYPE OF REPORTING PERSON\*

IN

-----  
\*SEE INSTRUCTIONS BEFORE FILLING OUT

Page 5 of 7 pages

Item 1.

- (a) Name of Issuer:  
Cytoclonal Pharmaceuticals Inc.
- (b) Address of Issuer's Principal Executive Offices:  
9000 Harry Hines Boulevard  
Dallas, TX 75232

Item 2.

- (a) Name of Person Filing:
- Kinder Investments, L.P. ("Kinder Investments"); Peyser Associates, LLC ("Peyser"), the general partner of Kinder Investments; and Brian A. Wasserman ("Wasserman"), the managing member of Peyser (together, the "Reporting Parties"). See attached Exhibit A which is their agreement to file this Schedule on behalf of each of them.
- (b) Address of Principal Business Office or, if None, Residence:
- The Reporting Parties' business address is 1500 Hempstead Turnpike, East Meadow, New York 11554.
- (c) Citizen:
- Kinder Investments is a New York partnership, Peyser is a New York corporation, and Wasserman is a citizen of the United States.
- (d) Title of Class of Securities:  
Common Stock, \$.01 par value ("shares").
- (e) CUSIP#: 23282G105

Item 4. Ownership:

- (a)(b) As of December 31, 1997, the Reporting Parties may be deemed to

beneficially own 708,000 shares or 8.1% of the Issuer's shares as follows: (i) 668,000 shares owned directly by Kinder Investments, and (ii) warrants to purchase 40,000 shares at an exercise price of \$3.75 per share, expiring November 2, 2000 owned directly by Kinder Investments.

- (c) Wasserman, as the managing member of Peyser, has sole voting and dispositive control of shares owned by Kinder Investments.

Item 5. Ownership of Five Percent or Less of a Class:

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

Not applicable.

Page 6 of 7 pages

Item 8. Identification and Classification of Members of the Group:

Not applicable.

Item 9. Notice of Dissolution of Group:

Not applicable.

Item 10. Certification:

By signing below we certify that to the best of our knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as participant in any transaction having such purpose of effect.

SIGNATURES

After reasonable inquiry and to the best knowledge and belief of the Reporting Persons, each such person or entity certifies that the information set forth in this statement is true, complete and correct.

Kinder Investments, L.P.

/s/ Brian A. Wasserman

Dated: April 8, 1998

By: \_\_\_\_\_

New York, New York

Brian A. Wasserman

Managing Member

Peyser Associates, LLC

Peyser Associates, LLC

/s/ Brian A. Wasserman  
Dated: April 8, 1998 By: \_\_\_\_\_  
New York, New York Brian A. Wasserman  
Managing Member

/s/ Brian A. Wasserman  
Dated: April 8, 1998 \_\_\_\_\_  
Brian A. Wasserman

EXHIBIT A

AGREEMENT

JOINT FILING OF SCHEDULE 13G

The Undersigned hereby agree to jointly prepare and file with regulatory authorities a Schedule 13G and any future amendments thereto reporting each of the undersigned's ownership of securities of Cytoclonal Pharmaceuticals Inc. and hereby affirm that such Schedule 13G is being filed on behalf of each of the undersigned.

Kinder Investments, L.P.

/s/ Brian A. Wasserman  
Dated: April 8, 1998 By: \_\_\_\_\_  
New York, New York Brian A. Wasserman  
Managing Member  
Peyser Associates, LLC

Peyser Associates, LLC

/s/ Brian A. Wasserman  
Dated: April 8, 1998 By: \_\_\_\_\_  
New York, New York Brian A. Wasserman  
Managing Member

/s/ Brian A. Wasserman  
Dated: April 8, 1998 \_\_\_\_\_  
Brian A. Wasserman